{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:23:17Z","timestamp":1780392197137,"version":"3.54.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The treatment landscape for chronic myeloid leukemia (CML) has been revolutionized by the introduction of imatinib, a tyrosine kinase inhibitor, which has transformed the disease from a fatal condition into a manageable chronic illness for a substantial number of patients. Despite this, some individuals do not respond adequately to the treatment, and others may experience disease progression even with continued therapy. This study examined how <jats:italic>CYP2C8*3<\/jats:italic> (G416A; rs11572080) and <jats:italic>ABCG2<\/jats:italic> C421A (rs2231142) single nucleotide polymorphisms (SNPs) affect the plasma trough concentration and therapeutic response of imatinib in Egyptian CML patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study included fifty patients with chronic-phase CML, who were categorized into two groups: responders (<jats:italic>n<\/jats:italic>\u2009=\u200926) and non-responders (<jats:italic>n<\/jats:italic>\u2009=\u200924), according to their <jats:italic>BCR-ABL1<\/jats:italic> transcription levels after 12 months of imatinib treatment. Genotyping of the <jats:italic>CYP2C8*3<\/jats:italic> and <jats:italic>ABCG2<\/jats:italic> C421A polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), while plasma trough concentrations were determined through high-performance liquid chromatography with ultraviolet-diode array detection (HPLC-UV\/DAD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients with the CA genotype of <jats:italic>ABCG2<\/jats:italic> C421A showed significantly higher mean plasma trough concentrations of imatinib (CA: 1731\u2009\u00b1\u2009424.7 ng\/mL; CC: 1294\u2009\u00b1\u2009381.3 ng\/mL; <jats:italic>p<\/jats:italic>\u2009=\u20090.0132) and demonstrated a better molecular response compared to those with the CC genotype (<jats:italic>p<\/jats:italic>\u2009=\u20090.0395).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The <jats:italic>ABCG2<\/jats:italic> C421A polymorphism significantly influenced imatinib plasma trough concentrations and molecular responses in Egyptian chronic-phase CML patients. Genotyping of this polymorphism in these patients could assist in optimizing imatinib therapy, predicting more favorable treatment outcomes, and enabling the development of more personalized treatment plans.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-024-04723-y","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T07:08:14Z","timestamp":1734937694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"95","author":[{"given":"Safwat A.","family":"Mangoura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud H.","family":"Abdel-Raheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan A.","family":"Eltyb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-6152","authenticated-orcid":false,"given":"Mohammed S.","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer M. R.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"issue":"10314","key":"4723_CR1","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01891-8","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S (2021) Chronic myeloid leukaemia. Lancet 398(10314):1914\u20131926. https:\/\/doi.org\/10.1016\/S0140-6736(21)01891-8","journal-title":"Lancet"},{"key":"4723_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","volume":"35","author":"ZJ Kang","year":"2016","unstructured":"Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, Liu Q (2016) The Philadelphia chromosome in leukemogenesis. Chin J Cancer 35:48. https:\/\/doi.org\/10.1186\/s40880-016-0108-0","journal-title":"Chin J Cancer"},{"issue":"4","key":"4723_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11010-022-04474-0","volume":"477","author":"V Kumar","year":"2022","unstructured":"Kumar V, Singh P, Gupta SK, Ali V, Verma M (2022) Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem 477(4):1261\u20131279. https:\/\/doi.org\/10.1007\/s11010-022-04474-0","journal-title":"Mol Cell Biochem"},{"key":"4723_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.03.003","volume":"120","author":"N Harivenkatesh","year":"2017","unstructured":"Harivenkatesh N, Kumar L, Bakhshi S, Sharma A, Kabra M, Velpandian T, Gogia A, Shastri SS, Biswas NR, Gupta YK (2017) Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Pharmacol Res 120:138\u2013145. https:\/\/doi.org\/10.1016\/j.phrs.2017.03.003","journal-title":"Pharmacol Res"},{"issue":"1","key":"4723_CR5","doi-asserted-by":"publisher","first-page":"20640","DOI":"10.1038\/s41598-020-77691-6","volume":"10","author":"BM Rajamani","year":"2020","unstructured":"Rajamani BM, Benjamin ES, Abraham A, Ganesan S, Lakshmi KM, Anandan S, Karathedath S, Varatharajan S, Mohanan E, Janet NB, Srivastava VM (2020) Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients. Sci Rep 10(1):20640. https:\/\/doi.org\/10.1038\/s41598-020-77691-6","journal-title":"Sci Rep"},{"issue":"1","key":"4723_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14728214.2018.1400461","volume":"23","author":"S Kavanagh","year":"2018","unstructured":"Kavanagh S, Nee A, Lipton JH (2018) Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. Expert Opin Emerg Drugs 23(1):51\u201362. https:\/\/doi.org\/10.1080\/14728214.2018.1400461","journal-title":"Expert Opin Emerg Drugs"},{"key":"4723_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0808-x","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G (2018) Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer 17:49. https:\/\/doi.org\/10.1186\/s12943-018-0808-x","journal-title":"Mol Cancer"},{"issue":"8","key":"4723_CR8","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022\u20134028. https:\/\/doi.org\/10.1182\/blood-2007-10-116475","journal-title":"Blood"},{"issue":"5","key":"4723_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3324\/haematol.2011.056200","volume":"97","author":"F Guilhot","year":"2012","unstructured":"Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y (2012) Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and selectivity trial. Haematologica 97(5):731\u2013738. https:\/\/doi.org\/10.3324\/haematol.2011.056200","journal-title":"Haematologica"},{"issue":"5","key":"4723_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.693","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JH, Beijnen JH, Steeghs N, Huitema AD (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102(5):765\u2013776. https:\/\/doi.org\/10.1002\/cpt.693","journal-title":"Clin Pharmacol Ther"},{"key":"4723_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40262-016-0442-2","volume":"56","author":"S Farag","year":"2017","unstructured":"Farag S, Verheijen RB, Martijn Kerst J, Cats A, Huitema AD, Steeghs N (2017) Imatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patients. Clin Pharmacokinet 56:287\u2013292. https:\/\/doi.org\/10.1007\/s40262-016-0442-2","journal-title":"Clin Pharmacokinet"},{"key":"4723_CR12","doi-asserted-by":"publisher","unstructured":"Barratt DT, Somogyi AA (2017) Role of pharmacogenetics in personalised imatinib dosing. Transl Cancer Res 6(Suppl 10). https:\/\/doi.org\/10.21037\/tcr.2017.06.01. S1541-S1557","DOI":"10.21037\/tcr.2017.06.01"},{"issue":"12","key":"4723_CR13","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1002\/jps.24126","volume":"103","author":"J Shao","year":"2014","unstructured":"Shao J, Markowitz JS, Bei D, An G (2014) Enzyme-transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 103(12):3810\u20133833. https:\/\/doi.org\/10.1002\/jps.24126","journal-title":"J Pharm Sci"},{"issue":"10","key":"4723_CR14","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/bcp.13328","volume":"83","author":"NA Lankheet","year":"2017","unstructured":"Lankheet NA, Desar IM, Mulder SF, Burger DM, Kweekel DM, van Herpen CM, van der Graaf WT, van Erp NP (2017) Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol 83(10):2195\u20132204. https:\/\/doi.org\/10.1111\/bcp.13328","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"4723_CR15","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01717.x","volume":"165","author":"AM Filppula","year":"2012","unstructured":"Filppula AM, Laitila J, Neuvonen PJ, Backman JT (2012) Potent mechanism-based inhibition of CYP3A4 by Imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165(8):2787\u20132798. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01717.x","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4723_CR16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00924.x","volume":"161","author":"N Nebot","year":"2010","unstructured":"Nebot N, Crettol S, d\u2019Esposito F, Tattam B, Hibbs DE, Murray M (2010) Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161(5):1059\u20131069. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00924.x","journal-title":"Br J Pharmacol"},{"issue":"1","key":"4723_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1124\/dmd.112.046094","volume":"41","author":"AM Filppula","year":"2013","unstructured":"Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT (2013) Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos 41(1):50\u201359. https:\/\/doi.org\/10.1124\/dmd.112.046094","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4723_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/annonc\/mds501","volume":"24","author":"SJ Seong","year":"2013","unstructured":"Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW (2013) Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 24(3):756\u2013760. https:\/\/doi.org\/10.1093\/annonc\/mds501","journal-title":"Ann Oncol"},{"key":"4723_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544080-00002","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894. https:\/\/doi.org\/10.2165\/00003088-200544080-00002","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4723_CR20","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172\u20132175. https:\/\/doi.org\/10.1038\/leu.2012.104","journal-title":"Leukemia"},{"issue":"4","key":"4723_CR21","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"11","key":"4723_CR22","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.3109\/10428194.2014.898748","volume":"55","author":"H Malhotra","year":"2014","unstructured":"Malhotra H, Sharma P, Bhargava S, Rathore OS, Malhotra B, Kumar M (2014) Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia. Leuk Lymphoma 55(11):2614\u20132619. https:\/\/doi.org\/10.3109\/10428194.2014.898748","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4723_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/analytica3030031","volume":"3","author":"B Bruijns","year":"2022","unstructured":"Bruijns B, Hoekema T, Oomens L, Tiggelaar R, Gardeniers H (2022) Performance of spectrophotometric and fluorometric DNA quantification methods. Analytica 3(3):371\u2013384. https:\/\/doi.org\/10.3390\/analytica3030031","journal-title":"Analytica"},{"issue":"7","key":"4723_CR24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1089\/gtmb.2011.0332","volume":"16","author":"K Pechandova","year":"2012","unstructured":"Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O (2012) Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers 16(7):812\u2013816. https:\/\/doi.org\/10.1089\/gtmb.2011.0332","journal-title":"Genet Test Mol Biomarkers"},{"key":"4723_CR25","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00432-014-1695-1","volume":"140","author":"HO El Mesallamy","year":"2014","unstructured":"El Mesallamy HO, Rashed WM, Hamdy NM, Hamdy N (2014) High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next? J Cancer Res Clin Oncol 140:1359\u20131365. https:\/\/doi.org\/10.1007\/s00432-014-1695-1","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"4723_CR26","first-page":"1495","volume":"73","author":"M Kaza","year":"2016","unstructured":"Kaza M, Piorkowska E, Filist M, Rudzki PJ (2016) HPLC-UV assay of imatinib in human plasma optimized for bioequivalence studies. Acta Pol Pharm 73(6):1495\u20131503","journal-title":"Acta Pol Pharm"},{"issue":"5","key":"4723_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2217\/pgs-2018-0017","volume":"19","author":"R Ankathil","year":"2018","unstructured":"Ankathil R, Azlan H, Dzarr AA, Baba AA (2018) Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. Pharmacogenomics 19(5):475\u2013493. https:\/\/doi.org\/10.2217\/pgs-2018-0017","journal-title":"Pharmacogenomics"},{"issue":"1","key":"4723_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.08.002","volume":"274","author":"G Volpe","year":"2009","unstructured":"Volpe G, Panuzzo C, Ulisciani S, Cilloni D (2009) Imatinib resistance in CML. Cancer Lett 274(1):1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2008.08.002","journal-title":"Cancer Lett"},{"issue":"2","key":"4723_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.068676","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW (2013) Association between Imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 98(2):193\u2013200. https:\/\/doi.org\/10.3324\/haematol.2012.068676","journal-title":"Haematologica"},{"issue":"3","key":"4723_CR30","doi-asserted-by":"publisher","first-page":"e8751","DOI":"10.1002\/ece3.8751","volume":"12","author":"CF Kratochwil","year":"2022","unstructured":"Kratochwil CF, Kautt AF, Rometsch SJ, Meyer A (2022) Benefits and limitations of a new genome-based PCR\u2010RFLP genotyping assay (GB\u2010RFLP): a SNP\u2010based detection method for identification of species in extremely young adaptive radiations. Ecol Evol 12(3):e8751. https:\/\/doi.org\/10.1002\/ece3.8751","journal-title":"Ecol Evol"},{"key":"4723_CR31","doi-asserted-by":"publisher","first-page":"646130","DOI":"10.3389\/fevo.2021.646130","volume":"9","author":"D Jordan","year":"2021","unstructured":"Jordan D, Mills D (2021) Past, present, and future of DNA typing for analyzing human and non-human forensic samples. Front Ecol Evol 9:646130. https:\/\/doi.org\/10.3389\/fevo.2021.646130","journal-title":"Front Ecol Evol"},{"key":"4723_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10989-012-9321-0","volume":"19","author":"M Caterino","year":"2013","unstructured":"Caterino M, Casadei GM, Arvonio R, De Francia S, Pirro E, Piccione FM, Pane F, Ruoppolo M (2013) Quantification of imatinib plasma levels in patients with chronic myeloid leukemia: comparison between HPLC\u2013UV and LC\u2013MS\/MS. Int J Pept Res Ther 19:109\u2013116. https:\/\/doi.org\/10.1007\/s10989-012-9321-0","journal-title":"Int J Pept Res Ther"},{"issue":"1","key":"4723_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.dmpk.2015.09.002","volume":"31","author":"M Miura","year":"2016","unstructured":"Miura M, Takahashi N (2016) Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC\u2013UV or LC\u2013MS\/MS methods. Drug Metab Pharmacokinet 31(1):12\u201320. https:\/\/doi.org\/10.1016\/j.dmpk.2015.09.002","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3\u20134","key":"4723_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.cca.2009.10.007","volume":"411","author":"O Roth","year":"2010","unstructured":"Roth O, Spreux-Varoquaux O, Bouchet S, Rousselot P, Castaigne S, Rigaudeau S, Raggueneau V, Therond P, Devillier P, Molimard M, Maneglier B (2010) Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS\/MS. Clin Chim Acta 411(3\u20134):140\u2013146. https:\/\/doi.org\/10.1016\/j.cca.2009.10.007","journal-title":"Clin Chim Acta"},{"issue":"12","key":"4723_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/FPC.0000000000000004","volume":"23","author":"CL Aquilante","year":"2013","unstructured":"Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE (2013) PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics 23(12):721\u2013728. https:\/\/doi.org\/10.1097\/FPC.0000000000000004","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"4723_CR36","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.685","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 102(4):688\u2013700. https:\/\/doi.org\/10.1002\/cpt.685","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4723_CR37","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10903-021-01275-2","volume":"24","author":"S Abudahab","year":"2022","unstructured":"Abudahab S, Hakooz N, Tobeh N, Gogazeh E, Gharaibeh M, Al-Eitan L, Zihlif M, Dajani R (2022) Variability of CYP2C8 polymorphisms in three Jordanian populations: circassians, chechens, and Jordanian-Arabs. J Immigr Minor Health 24(5):1167\u20131176. https:\/\/doi.org\/10.1007\/s10903-021-01275-2","journal-title":"J Immigr Minor Health"},{"key":"4723_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.apha.2018.03.001","volume":"83","author":"A Tornio","year":"2018","unstructured":"Tornio A, Backman JT (2018) Cytochrome P450 in pharmacogenetics: an update. Adv Pharmacol 83:3\u201332. https:\/\/doi.org\/10.1016\/bs.apha.2018.03.001","journal-title":"Adv Pharmacol"},{"issue":"3","key":"4723_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/00498254.2015.1060367","volume":"46","author":"MS Khan","year":"2016","unstructured":"Khan MS, Barratt DT, Somogyi AA (2016) Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica 46(3):278\u2013287. https:\/\/doi.org\/10.3109\/00498254.2015.1060367","journal-title":"Xenobiotica"},{"issue":"1","key":"4723_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2125.2012.04328.x","volume":"75","author":"CL Aquilante","year":"2013","unstructured":"Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M (2013) Impact of the CYP2C8*3 polymorphism on the drug\u2013drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 75(1):217\u2013226. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04328.x","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4723_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/FPC.0000000000000282","volume":"27","author":"MC Verboom","year":"2017","unstructured":"Verboom MC, Visser L, Kouwen S, Swen JJ, Diepstraten J, Posthuma WF, Gelderblom H, Van Lammeren D, Wilms EB (2017) Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Pharmacogenet Genomics 27(6):223\u2013226. https:\/\/doi.org\/10.1097\/FPC.0000000000000282","journal-title":"Pharmacogenet Genomics"},{"key":"4723_CR42","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40262-016-0505-y","volume":"56","author":"DT Barratt","year":"2017","unstructured":"Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA (2017) CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukemia patients. Clin Pharmacokinet 56:977\u2013985. https:\/\/doi.org\/10.1007\/s40262-016-0505-y","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4723_CR43","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/bcp.15572","volume":"89","author":"C Dalle Fratte","year":"2023","unstructured":"Dalle Fratte C, Gagno S, Roncato R, Polesel J, Zanchetta M, Buzzo M, Posocco B, De Mattia E, Borsatti R, Puglisi F, Foltran L (2023) CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients. Br J Clin Pharmacol 89(3):1089\u20131098. https:\/\/doi.org\/10.1111\/bcp.15572","journal-title":"Br J Clin Pharmacol"},{"key":"4723_CR44","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1007\/s00018-021-03910-x","volume":"78","author":"S Kukal","year":"2021","unstructured":"Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, Saso L (2021) Multidrug efflux transporter ABCG2: expression and regulation. Cell Mol Life Sci 78:6887\u20136939. https:\/\/doi.org\/10.1007\/s00018-021-03910-x","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"4723_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17425255.2021.1896652","volume":"17","author":"H Bruckmueller","year":"2021","unstructured":"Bruckmueller H, Cascorbi I (2021) ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? Expert Opin Drug Metab Toxicol 17(4):369\u2013396. https:\/\/doi.org\/10.1080\/17425255.2021.1896652","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"25","key":"4723_CR46","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1073\/pnas.0902308106","volume":"106","author":"OM Woodward","year":"2009","unstructured":"Woodward OM, K\u00f6ttgen A, Coresh J, Boerwinkle E, Guggino WB, K\u00f6ttgen M (2009) Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 106(25):10338\u201311042. https:\/\/doi.org\/10.1073\/pnas.0902308106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4723_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/17425255.2019.1574854","volume":"15","author":"Z Safar","year":"2019","unstructured":"Safar Z, Kis E, Erdo F, Zolnerciks JK, Krajcsi P (2019) ABCG2\/BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol 15(4):313\u2013328. https:\/\/doi.org\/10.1080\/17425255.2019.1574854","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"4723_CR48","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/FPC.0000000000000348","volume":"27","author":"AE Fohner","year":"2017","unstructured":"Fohner AE, Brackman DJ, Giacomini KM, Altman RB, Klein TE (2017) PharmGKB summary: very important pharmacogene information for: ABCG2. Pharmacogenet Genomics 27(11):420\u2013427. https:\/\/doi.org\/10.1097\/FPC.0000000000000348","journal-title":"Pharmacogenet Genomics"},{"issue":"13","key":"4723_CR49","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1073\/pnas.1219808110","volume":"110","author":"OM Woodward","year":"2013","unstructured":"Woodward OM, Tukaye DN, Cui J, Greenwell P, Constantoulakis LM, Parker BS, Rao A, K\u00f6ttgen M, Maloney PC, Guggino WB (2013) Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. Proc Natl Acad Sci U S A 110(13):5223\u20135228. https:\/\/doi.org\/10.1073\/pnas.1219808110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"4723_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/jhg.2010.108","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, Saitoh H, Fujishima N, Yoshioka T, Hirokawa M, Sawada K (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55(11):731\u2013737. https:\/\/doi.org\/10.1038\/jhg.2010.108","journal-title":"J Hum Genet"},{"issue":"1","key":"4723_CR51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pgs-2016-0047","volume":"18","author":"ZP Jiang","year":"2017","unstructured":"Jiang ZP, Zhao XL, Takahashi N, Angelini S, Dubashi B, Sun L, Xu P (2017) Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics 18(1):35\u201356. https:\/\/doi.org\/10.2217\/pgs-2016-0047","journal-title":"Pharmacogenomics"},{"issue":"17","key":"4723_CR52","doi-asserted-by":"publisher","first-page":"9815","DOI":"10.3390\/ijms23179815","volume":"23","author":"R Alves","year":"2022","unstructured":"Alves R, Gon\u00e7alves AC, Jorge J, Marques G, Ribeiro AB, Tenreiro R, Coucelo M, Diamond J, Oliveiros B, Pereira A, Freitas-Tavares P (2022) Genetic variants of ABC and SLC transporter genes and chronic myeloid leukemia: impact on susceptibility and prognosis. Int J Mol Sci 23(17):9815. https:\/\/doi.org\/10.3390\/ijms23179815","journal-title":"Int J Mol Sci"},{"key":"4723_CR53","doi-asserted-by":"publisher","first-page":"112090","DOI":"10.1016\/j.intimp.2024.112090","volume":"133","author":"F Cheng","year":"2024","unstructured":"Cheng F, Cui Z, Li Q, Chen S, Li W, Zhang Y (2024) Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia. Int Immunopharmacol 133:112090. https:\/\/doi.org\/10.1016\/j.intimp.2024.112090","journal-title":"Int Immunopharmacol"},{"key":"4723_CR54","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00280-015-2871-8","volume":"76","author":"J Francis","year":"2015","unstructured":"Francis J, Dubashi B, Sundaram R, Pradhan SC, Chandrasekaran A (2015) A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients. Cancer Chemother Pharmacol 76:1185\u20131189. https:\/\/doi.org\/10.1007\/s00280-015-2871-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"4723_CR55","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3389\/fonc.2020.01348","volume":"10","author":"MM Omran","year":"2020","unstructured":"Omran MM, Abdelfattah R, Moussa HS, Alieldin N, Shouman SA (2020) Association of the trough, peak\/trough ratio of imatinib, pyridine\u2013N-oxide imatinib and ABCG2 SNPs 34 G\u2009>\u2009A and SLCO1B3 334 T\u2009>\u2009G with imatinib response in Egyptian chronic myeloid leukemia patients. Front Oncol 10:1348. https:\/\/doi.org\/10.3389\/fonc.2020.01348","journal-title":"Front Oncol"},{"issue":"3","key":"4723_CR56","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1055\/a-1924-7746","volume":"73","author":"A Sabri","year":"2023","unstructured":"Sabri A, Omran MM, Azim SA, Abdelfattah R, Allam RM, Shouman SA (2023) Role of IDH1 (R132) mutation on imatinib toxicity and effect of ABCG2\/OCT1 expression on N-desmethyl imatinib plasma level in Egyptian chronic myeloid leukemia patients. Drug Res (Stuttg) 73(3):146\u2013155. https:\/\/doi.org\/10.1055\/a-1924-7746","journal-title":"Drug Res (Stuttg)"},{"key":"4723_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43042-023-00467-0","volume":"24","author":"N Nouri","year":"2023","unstructured":"Nouri N, Mehrzad V, Khalaj Z, Zaker E, Zare F, Abbasi E, Khosravi M, Kalantar SM, Salehi M (2023) Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients. Egypt J Med Hum Genet 24:1. https:\/\/doi.org\/10.1186\/s43042-023-00467-0","journal-title":"Egypt J Med Hum Genet"},{"key":"4723_CR58","doi-asserted-by":"publisher","first-page":"107021","DOI":"10.1016\/j.leukres.2023.107021","volume":"126","author":"F Mohammadi","year":"2023","unstructured":"Mohammadi F, Rostami G, Hamid M, Shafiei M, Azizi M, Bahmani H (2023) Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients. Leuk Res 126:107021. https:\/\/doi.org\/10.1016\/j.leukres.2023.107021","journal-title":"Leuk Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04723-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04723-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04723-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T19:02:17Z","timestamp":1734980537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04723-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4723"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04723-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In the preparation of this manuscript, generative AI, specifically OpenAI\u2019s ChatGPT, was utilized to support the writing process. ChatGPT was employed to assist with language refinement, editing, and the restructuring of certain passages to ensure clarity and adherence to scientific writing standards. The use of AI was guided by the authors, who provided all the intellectual content and made final decisions on the presentation and interpretation of the research findings. All AI-generated text was carefully reviewed and edited by the authors to align with the scientific rigor and standards expected of the manuscript. The final content of the manuscript is the result of the authors\u2019 original work and expertise.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}